#biosimilars — Public Fediverse posts

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

5 successful phase III oncology trials in Q1—FDA gives nod to BrainStorm for ALS trial after Phase III flop—AbbVie’s Humira loses only 4% of market share to biosimilars--http://bit.ly/w28kSd #clinicaltrials #oncology #fda #als #abbvie #humira #biosimilars #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

5 successful phase III oncology trials in Q1—FDA gives nod to BrainStorm for ALS trial after Phase III flop—AbbVie’s Humira loses only 4% of market share to biosimilars--http://bit.ly/w28kSd #clinicaltrials #oncology #fda #als #abbvie #humira #biosimilars #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie’s Humira maintains market dominance amid biosimilar launches —Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts — Novartis ends phase III peanut allergy trial --http://bit.ly/w28kSd #biosimilars #humira #abbvie #bayer #restructuring #layoffs #novartis #clinicaltrials #peanutallergy #novartis #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

CVS to remove AbbVie’s Humira from reimbursement lists, cover biosimilars-- Lilly launches website, home delivery option for weight-loss drugs— Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals --http://bit.ly/w28kSd #cvs #abbvie #biosimilars #humira #weightloss #elililly #novonordisk #mash #nash #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Roche joins obesity drug chase with $2.7B deal for startup Carmot-- Humira biosimilars not gaining traction --JNJ hires thousands, invests millions in AI-powered drug discovery --http://bit.ly/w28kSd #roche #mergersandacquisitions #obesity #humira #biosimilars #abbvie #jnj #ai #drugdiscovery #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AstraZeneca refused to pay full bonus to US remote worker, lawsuit claims -- Third time might be the charm for Alvotech's Humira biosimilar -- Roche scores—again—in hemophilia drug patent case against Takeda -- See more on our front page news http://bit.ly/w28kSd #astrazeneca #remotework #legal #employmentlaw #alovtech #humira #abbvie #fda #biosimilars #roche #genenetech #takeda #patents #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's Humira to take hit from biosimilars, next-gen therapies -- Walgreens to pay $44M to settle claims over fraudulent Theranos tests -- AstraZeneca signs AI-powered drug discovery pact with Verge -- See more on our front page news http://bit.ly/w28kSd #abbvie #humira #biosimilars #walgreens #theranos #legal #fraud #medtech #astrazeneca #ai #drugdiscovery #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Amgen clinches clinical wins in SCLC and colorectal cancer -- FDA approves Merck's Ebola vaccine for under-18s -- Amgen's hyped Humira biosimilar fritters away its exclusivity advantage -- See more on our front page news http://bit.ly/w28kSd #amgen #clinicaltrials #lungcancer #colorectalcancer #humira #biosimilars #vaccines #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Pfizer shuffles R&D leadership to prepare for Seagen merger -- Lilly's obesity drug leads to about 26% weight loss in new studies -- Biosimilar makers split strategies in bid to take on top-selling Humira -- See more on our front page news http://bit.ly/w28kSd #pfizer #mergersandacquisitions #seagen #researchanddevelopment #biosimilars #abbvie #humira #obesity #clinicaltrials #elililly #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

7 life science IPOs in 2023 — 7 companies are rolling out Humira biosimilars -- Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns -- See more on our front page news http://bit.ly/w28kSd #ipos #lifesciences #biosimilars #abbvie #humira #opdivo #bladdercancer #bristolmyerssquibb #merck #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

FDA rejects Teva’s high-potency biosimilar of Humira again — After a record run, fewer biotechs are going public— Sarepta shares drop as report says FDA almost rejected under-review gene therapy -- See more on our front page news http://bit.ly/w28kSd #tevapharma #fda #humira #abbvie #biosimilars #ipos #genetherapy #sarepta #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Thanks To Evergreening And Legal Threats, AbbVie Has Earned $114 Billion Since 2016 From A Drug Whose Key Patent Expired Back Then

https://www.techdirt.com/2023/02/10/thanks-to-evergreening-and-legal-threats-abbvie-has-earned-114-billion-since-2016-from-a-drug-whose-key-patent-expired-back-then/

#evergreening #biosimilars #drugpatents #monopolies #arthritis #mckinsey #patents #abbvie #humira

Thanks To Evergreening And Legal Threats, AbbVie Has Earned $114 Billion Since 2016 From A Drug Whose Key Patent Expired Back Then

https://www.techdirt.com/2023/02/10/thanks-to-evergreening-and-legal-threats-abbvie-has-earned-114-billion-since-2016-from-a-drug-whose-key-patent-expired-back-then/

#evergreening #biosimilars #drugpatents #monopolies #arthritis #mckinsey #patents #abbvie #humira

Amgen, navigating 'industry headwinds,' puts 300 commercial jobs on chopping block — The end of the Humira era — Biotech pipeline hosts 163 potential meds for mental illness, with depression dominating -- See more on our front page news http://bit.ly/w28kSd #amgen #layoffs #humira #biosimilars #abbvie #biotech #pipeline #mentalhealth #mentalillness #depression #pharma #pharmanews #biotechnology #biopharma #cafepharma